February 1, 2017 09:26 AM EST
R&D

Strug­gling Oph­thotech or­ga­nizes a glob­al hunt for some new opthal­mol­o­gy deals

Arsalan Arif

Founder

Oph­thotech wast­ed lit­tle time in re­spond­ing to its Phase III Fo­vista dis­as­ter by lay­ing off 135 staffers and hun­ker­ing down to weath­er the storm. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times